Objectives. Patient-reported outcome (PRO) measures are often used to diagnose laryngopharyngeal reflux (LPR) and monitor treatment outcomes in clinical and research settings. The present systematic review was designed to identify currently available LPR-related PRO measures and to evaluate each measure's instrument development, validation, and applicability. Data Sources. MEDLINE via PubMed interface, CINAHL, and Health and Psychosocial Instrument databases were searched with relevant vocabulary and key terms related to PRO measures and LPR.
G astroesophageal reflux disease (GERD) affects an estimated 40% of the US population. 1 Increased attention to GERD has shifted focus to whether reflux influences other physiologic processes beyond the esophagus. Anecdotes dating back to 1960s have hypothesized connections between reflux and hoarseness, 2,3 cancer, 4 and airway pathologies. 5, 6 In 1991, Koufman operationalized laryngopharyngeal reflux (LPR), finding that it had a greater consequence on laryngeal function than previously considered. 7 A distinction was made positing that LPR patients do not necessarily have classic GERD symptoms; rather, a large proportion have ''silent reflux'' that manifests in sundry upper airway symptoms. 8 A sensitive and specific gold standard objective diagnostic test to consistently identify patients affected by LPR remains elusive despite rapid technological advancements and vast expenditure on the subject. 9 Efforts to correlate specific endoscopic findings and the presence of reflux have thus far met with little success. [10] [11] [12] Despite the lack of pathognomonic signs, LPR has become a primary diagnosis and has resulted in patients experiencing a barrage of medications, specialty physician visits, diagnostic tests, and operations. 9 In the absence of a definitive diagnostic test, patient symptoms have become a primary method to identify those with LPR. Symptomatic differentiation of GERD and LPR should be possible if they indeed have discrete phenotypes. Therefore, patient-reported outcome (PRO) measures have become a principal means to diagnose LPR and monitor treatment outcomes. However, if PRO measures are to be used to make patient-centered, symptom-based diagnoses and treatment decisions, they must be designed with appropriate methodological rigor. Use of poorly developed measures or those intended for a different application can have significant implications and lead to distorted, inaccurate, or equivocal findings. 13, 14 Few clinicians or researchers have expertise in the technical methods used to develop and validate these instruments. Hence, many may presume that published PRO measures have comparably strong and appropriate measurement properties, precision, and applicability. This is problematic since nearly all published instruments purport some degree of these attributes, most often as forms of reliability or validity. 15 The aim of the present study was to perform a comprehensive systematic review of the literature on LPR-related PRO measures and to rigorously evaluate each measure's developmental properties, validation, and applicability.
Methods
This study did not involve data collection from or about human subjects and was therefore exempt from Institutional Review Board approval. The systematic review methodology used herein strictly adhered to PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-analyses). 16 
Search Strategy
An expert librarian searched MEDLINE via the PubMed interface, CINAHL, and the Health and Psychosocial Instrument database without publication date restrictions, using relevant vocabulary terms and key terms related to PRO measures and swallowing disorders, including laryngopharyngeal and extraesophageal reflux ( Table 1) . The search was performed in July 2015 and limited to Englishlanguage publications. Reference lists of included articles and reviews that were related to measurement of LPR were hand-searched to identify potentially pertinent articles.
Study Selection
We developed inclusion and exclusion criteria in consultation with an expert panel that included a statistician with expertise in measurement theory, a research librarian, systematic review methodologists, and researchers and clinicians who study and treat LPR. Three investigators (D.O.F., R.S., D.A.P.) independently reviewed abstracts for all identified studies, and those meeting predetermined criteria ( Table 2 ) were advanced to full text review. Abstracts that did not provide adequate information to determine eligibility were also advanced to full text review. We contacted authors of articles for supporting information when necessary.
PRO Measure Assessment
Three investigators independently assessed each study's methodology using a criterion checklist developed a priori ( Table 3) . 17 In brief, the checklist was designed to help systematic reviewers identify components deemed important to the development of PRO measures, including conceptual model, content validity, reliability, construct validity, scoring and interpretation, and respondent burden and presentation. Definitions of these concepts are provided in Table 4 . 
Domain Explanation
Conceptual model A conceptual model provides a rationale for and description of the concepts and target population that a measure is intended to assess.
Content validity
Content validity refers to evidence that a PRO measure's domains are appropriate for its intended use. Items and conceptual domains should be relevant to the target population's concerns. The PRO measure's development should include direct input from patients and also from content experts. There should be a clear description of the process by which included questions were derived. Reliability
Reliability is the degree to which scores are free from random (measurement) error. Internal consistency reliability-the degree to which segments of a test (eg, individual items) are associated with one another-reflects precision at a single time point. Test-retest reliability refers to the reproducibility of scores over 2 administrations, typically in close temporal proximity, among respondents who are assumed not to have changed on the relevant domains. Traditionally cited minimum levels for reliability coefficients are 0.70 for group-level comparisons and 0.90 to 0.95 for individual comparisons. Reliability estimates lower than these conventions should be justified in the context of the proposed PRO measure's intended application.
Construct validity
Construct validity refers to whether a test measures intended theoretic constructs or traits and directly affects the appropriateness of the measurement-based inferences. Several different forms exist and are outlined below. Empirical demonstration of dimensionality (eg, factor analysis) provides evidence of whether a single scale or multiple subscales exist in the PRO measure. Responsiveness to change (longitudinal validity) is the extent to which a PRO measure detects meaningful change over time when it is known to have occurred. It is predicated on demonstration of both test-retest-reliability (stability when no change is expected) and clinically meaningful change when it is expected. Convergent validity is the degree to which a PRO measure's scores correlate with other instruments that measure the same construct or with related clinical indicators (eg, diagnostic test). A priori hypotheses about expected associations between a PRO measure and similar or dissimilar measures should be documented. Known-groups validity is the degree to which a PRO measure is able to differentiate among groups that empiric evidence has shown to be different (eg, cases and controls).
Interpretability and scoring
Interpretability is the degree to which the meaning of the scores can be easily understood. Scoring refers to the ''rules'' for computing total scores or scales, if relevant. A description of how to score the measure should be provided (eg, summation, algorithm). Missing responses are a common occurrence in clinical and research settings and can affect an end user's ability to interpret results. A prespecified plan for managing missing responses can mitigate the risk of bias resulting from the necessity to exclude cases with missing data. Scaling is the process of distributing the full range of respondents' possible scores with respect to the measured attribute. A relative score then represents a subject's location in relation to others on a common scale. It allows cross-sectional and longitudinal quantification of the magnitude of the attribute that is reported and its change over time. Cross-sectional and longitudinal changes in scores both need to be contextualized to allow interpretation of their meaning. Ideally, scaling should be based on an understanding of what represents a clinically important or patient-important change in the construct being measured.
Burden and presentation
Burden refers to the time, effort, or other demands placed on respondents or those administering the instrument. This includes number and complexity of items. The literacy level needed to understand and complete the measure is another important aspect of burden. While most experts recommend that literacy be at the sixth-grade reading level or lower, this criterion should be contextualized to the intended target population. Presentation refers to a questionnaire's appearance in light of its intended mode of administration. It is important that prospective users be able to preview a measure in its entirety (eg, items and response options) to ensure its appropriateness for the intended application.
Each reviewer was trained and calibrated on appropriate application of the checklist via a methodology described separately. 17 They were then independently tasked with evaluating all identified PRO measures. Upon completion, reviewers met to discuss and come to consensus on scoring discrepancies. A senior investigator and psychometrician (I.D.F.) adjudicated any remaining discrepancies.
Data Extraction
Components of PRO measure development were entered into evidence tables: name and acronym, authors, years published, objective and intended construct, setting of development (eg, tertiary care, community) and country, targeted population, type of scale used (eg, visual analog scale), number of items (ie, questions), and the presence of proposed subscales and what each was designed to measure.
Data Synthesis
Data from unique PRO measures demonstrated heterogeneity in constructs, methodology, and intended purpose and therefore were not appropriate for aggregation or metaanalysis. Instead, individual PRO characteristics, measurement properties, and functionality were summarized independently and in detail.
Results
A PRISMA diagram describing study flow and inclusions is shown in Figure 1 . Of 4947 studies reviewed, 7 provided initial developmental data on LPR-related PRO measures. Most excluded articles were not relevant to LPR or instrument development. The majority of measures were symptom indices related to LPR, 18-23 while 1 was intended to measure health-related quality of life among those with LPR. 24 The earliest instruments focused on globus and throat symptoms 18, 23 and the remainder on supraesophageal reflux (SER) 22 and LPR 19, 21, 23, 24 (Table 5) .
All related PRO measures were developed at tertiary care academic centers, although the Laryngopharyngeal Reflux-Health-Related Quality of Life questionnaire (LPR-HRQL) did also recruit patients from 1 regional medical center and 1 multispecialty group practice ( Table 6 ). 24 Country of study origin included the United States (n = 3), Great Britain (n = 3), and Sweden (n = 1), with years of publication ranging from 1991 to 2010 (Table 6) . 20, 23 Sample sizes used in development were extracted. These included targeted groups (eg, LPR-attributed symptoms) and the overall populations, which incorporated symptomatic subjects and nonaffected controls. Involved participants varied from 25 (targeted) and 50 (overall) to 279 and 985 in the Reflux Symptom Index (RSI) 21 and Supraesophageal Reflux Questionnaire (SERQ), 22 respectively. Mean or median age of patients across developmental samples ranged from 44.5 years in the Glasgow-Edinburgh Throat Scale (GETS) 18 to 59 years in the Pharyngeal Reflux Symptom Questionnaire (PRSQ). 23 Females were the majority in 5 of 6 remaining study samples (range, 44%-76%; Table 6 ). The study describing validation of the SERQ did not describe its cohort's age or sex distribution. 22 
Question Content
Compilation of questions from the various PRO measures revealed similarities. Figure 2 shows a categorized overall and measure-specific distribution of questions. The proportion of questions within each category differed among instruments. An overall mean was used to equally weight each measure as the number of items widely differed (range, . Overall percentages for question categories in these PRO measures are shown in the left column of Figure 2 . In order of frequency, questions were related to mucus/throat sensation (26%), throat clearing/cough (20%), swallowing (15%), voice (13%), reflux (13%), breathing (6%), other symptoms (4%) and general quality of life (3%). Instrument-specific distribution of questions by category is shown in the remainder of Figure 2 . Some measures directly incorporated questions from others. For example, the GETS included 6 verbatim questions from the Throat Questionnaire (TQ). 20 The 34-item Laryngopharyngeal Reflux questionnaire (LPR-34) 19 combined questions from the RSI 21 and Gastroesophageal Symptom Assessment Scale (GERD-related questions). 25 It did ''unbundle,'' thereby simplifying multibarreled items found in the RSI into unique questions. A paraphrased example of a multibarreled question from the RSI that contains 4 different processes into a single question is ''Within the last month, how did heartburn, chest pain, indigestion, or stomach acid coming up affect you?''
Developmental Characteristics
The developmental process and demonstrated measurement properties varied among identified PRO measures. Four instruments met at least 1 criterion from each of the 7 domains (RSI, PRSQ, GETS, and SERQ). 18, [21] [22] [23] Of the available measures, the PRSQ met the most criteria (16 of 18), followed by the RSI (13 of 18) and LPR-HRQL (13 of 18). None met all assessed criteria. Analyses based on domain are outlined in turn and summarized in Figure 3 .
Conceptual Model. Each identified PRO measure was judged to have defined the construct that it intended to measure and its respective target population. Six of 7 prespecified their expected dimensionality (eg, subscales) within the intended conceptual framework (Figure 3 ).
Content Validity.
Two PRO measures based question content on direct patient experience and symptoms derived from prospectively collected interviews or focus groups (LPR-HRQL, PRSQ). 23, 24 Question content for the remainder was based solely on the opinion of content experts who care for and study this population (eg, otolaryngologists, laryngologists, gastroenterologists, speech-language pathologists). In fact, content experts were ubiquitously involved in questionnaire content development. Four of 7 measures provided some description of the origin and rationale for selection of the final set of questions (LPR-HRQL, LPR-34, PRSQ, SERQ). 19, [22] [23] [24] Reliability. Six LPR-related PRO measures tested and demonstrated adequate reliability (ie, correlation coefficient r 0.70 or justified). Different types of reliability were evaluated. The RSI, SERQ, and TQ assessed test-retest reliability; the PRSQ and GETS computed internal consistency reliability; and the LPR-HRQL appraised both properties. The LPR-34 did not evaluate reliability.
Construct Validity. Most LPR-related PRO measures assessed some aspect of construct validity (GETS, RSI, LPR-HRQL, PRSQ, SERQ). 18, [21] [22] [23] [24] Three statistically justified their dimensionality-that is, whether multiple subscales or a single scale (ie, common factor) existed. 18, 23, 24 For example, the PRSQ performed exploratory factor analysis to identify and confirm its 4-domain structure related to LPR: cough, voice, dysphagia, and reflux. Four PRO measures established convergent validity by showing expected associations with other questionnaires focused on a similar construct (GETS, RSI, LPR-HRQL, PRSQ). 18, 21, 23, 24 None tested associations with clinical correlates.
All instruments had a stated goal of tracking outcomes longitudinally, but only the RSI 21 and LPR-HRQL 24 met the criterion of showing responsiveness to change. The RSI evaluated responsiveness by treating the 25 included subjects with LPR with a 6-month course of proton pump inhibitors. Each subject was readministered the RSI, and scores were shown to significantly improve from pre-to posttreatment (RSI score, 20.9 to 12.8). Responsiveness was calculated for the LPR-HRQL by assessing the change from baseline to 4-and 6-month PPI treatment end points. An a priori defined minimally important improvement in HRQL was achieved for all LPR-HRQL domains at both time points.
The RSI and PRSQ demonstrated known-group validity. For example, the RSI compared scores of 25 patients with symptoms attributed to LPR with 25 age-and sex-matched patients without this condition and found a significant difference in scores. A variant of criterion validity was assessed by the SERQ. The authors designated the treating physician's overall impression of SER as the ''gold standard,'' and patients were thus categorized by physician impression into 3 groups: (1) symptoms likely caused by SER, (2) symptoms not caused by SER, and (3) uncertain role of SER. Receiver operating characteristic curves were adjusted for chronic sinusitis and over-the-counter medication and yielded an area under the curve of 0.72. This value implies that the SERQ has a ''fair'' ability to discriminate patients who, physicians believe, have SER or not.
Interpretation and Scoring. Scoring approaches differed among PRO measures. Some used a simple summation, with higher total scores indicating higher degrees of the construct being measured. 18, 19, 23 However, most measures were not designed to yield an overall total score but rather to provide discrete, domain-specific scoring (TQ, SERQ, PRSQ, LPR-HRQL). 20, [22] [23] [24] Regarding missing data, only the PRSQ described a plan for managing incomplete questionnaires. In cases of PRSQ domains with missing items, nonmissing items within that given domain were rescaled to generate a value comparable to that of subjects responding to all items. If .50% of items within the domain were absent, the domain score was set as missing.
Three LPR-related measures provided some description of score scaling. 21, 23, 24 A minimum clinically meaningful change was calculated for all domains within the LPR-HRQL. Interestingly, this clinically important change was defined as that in each domain corresponding with a significant decrease (1 point) in the physician-reported symptom severity score. Thus, the minimally important change was determined via physician perception of severity, not necessarily by what mattered to the affected patients (eg, patientimportant difference). In contrast, the RSI and PRSQ used the same cutoff (RSI = 13) for what an abnormal score represents, thus dichotomizing normal versus abnormal. In neither case was scaling further delineated (eg, anchors, clinically important change, minimally important change).
Burden and Presentation. Five PRO measures were considered to have a reasonable degree of burden to the patient and administration (TQ, GETS, RSI, PRSQ, SERQ). 18, 20, 21, 23 Two instruments were considered overly burdensome owing to the number of questions (LPR-HRQL, LPR-34). 19, 24 No LPR-related measure offered an estimation of the literacy level needed for its comprehension or completion. Among identified instruments, 3 did not provide a readily accessible method of viewing the complete sets of included questions (LPR-HRQL, LPR-34, SERQ). 19, 22, 24 
Discussion
With growing emphasis on patient-centered outcomes and comparative effectiveness research, PRO measures have become a predominant method to systematically collect patient-centered data, monitor treatment outcomes, and direct clinical decision making. These instruments can be designed to quantify phenomena that lack a clear criterion. This is relevant for LPR where lack of a definitive diagnostic test has led to diagnostic uncertainty and controversy. Practitioners and researchers have proposed various approaches to diagnose LPR objectively, but each has been found inconsistent with suboptimal diagnostic sensitivity and specificity. [26] [27] [28] Consequently, most practicing clinicians rely on patient history and symptomatology to diagnose LPR and monitor treatment outcomes. 26 This is often quantified in clinical and research settings using PRO measures.
The appropriateness of using PRO measures for these purposes is predicated on their intent and developmental measurement properties. The present study systematically reviewed the literature on LPR-related PRO measures to assess their developmental characteristics, validation, and applicability. All 7 measures identified were designed to measure throat-related symptoms attributed to LPR, but they had disparate developmental rigor. The range of target individuals involved in development and/or validation of these measures varied significantly, from 25 to .273. 21, 22 It is generally recommended that variable and subject sampling be optimized for factor/principal components analysis-based methods and/or that there be .100 participants involved in validation. 29, 30 Four studies achieved this standard (TQ, SERQ, PRSQ, LPR-HRQL). 18, [22] [23] [24] Adequacy, applicability, and generalizability of measures that include few individuals from the target population in development should be questioned.
The development of LPR-related PRO measures has been hindered by several factors, including nonspecificity of LPR symptoms, lack of a sensitive and specific diagnostic test for LPR, and lack of laryngeal finding specificity. Nonspecificity of LPR symptoms has resulted, in part, in a diversity of question categories among instruments, which parallels the contemporary clinical picture of patients presumed to have LPR (eg, mucus/throat sensation, throat clearing/cough, dysphagia, dysphonia, reflux, dyspnea, general quality of life). In essence, LPR lacks a single clear pathognomonic symptom (or symptom cluster). The specificity of these PRO measures has been challenged. Recent studies have shown significant overlap between RSI scores suggestive of LPR and other nonreflux-related throat conditions. 31, 32 One found that patients with glottic insufficiency had pathologically elevated RSI scores, which normalized after its surgical correction with injection augmentation. 31 The lack of sensitivity and specificity of objective diagnostic tests for LPR has also affected how current measures have defined their target populations. Most studies enrolled participants who presented with throat or LPR-associated symptoms to an outpatient clinic [18] [19] [20] 22 or for pH monitoring, 23 without physiologic testing. In contrast, the RSI used ambulatory 24-hour double-probe pH monitoring to confirm its LPR diagnoses. 7, 33 While such physiologic testing is widely used to assess the presence of acid in the esophagus or hypopharynx of patients with LPR-related symptoms, its role in causally associating patients' symptoms to reflux remains controversial, with 70% and 50% sensitivities of distal and proximal probes, respectively. 27, 34 One PRO measure, the PRSQ, used laryngeal findings via the Reflux Finding Score to define the target population. 35 The specificity and reliability of this confirmatory test and laryngeal findings of LPR in general have been scrutinized and challenged by several studies. 12, [36] [37] [38] [39] [40] [41] Since its validation, 35 documented interrater agreement has ranged from poor to fair. 12, 37, 39, 41, 42 Moreover, the majority of asymptomatic controls have signs considered consistent with LPR. 10, 12, 43 Therefore, these signs may represent a tissue continuum that can be confounded by other processes (eg, allergic rhinitis, 41, 44 type of scope, 10, 45 prior knowledge of patient's symptoms 37 ) rather than distinct pathology. 38, 43 Our analysis focused on identifying and evaluating the developmental characteristics and functionality of PRO measures. All published measures purported reliability and/ or validity. This simple statement is often considered sufficient legitimization of a PRO measure's quality by end users. It is important to recognize that reliability and validity are not discrete concepts but rather exist on a spectrum. 46 Only the RSI met at least 1 criterion in each developmental domain. 18, [21] [22] [23] However, none met all criteria. Reasons for deficiencies are multifactorial.
Overall patient centeredness was lacking in LPR-related PRO measure development. Only the LPR-HRQL and PRSQ directly engaged patients in developing question content, despite all measures claiming to be patient centric. The foundation for PRO measures is the target population's perspective and experience. Thus, omitting patients at this stage compromises the content validity and fidelity of scores and creates a condition in which patients answer questions designed by and based on the experience and opinions of content experts who do not live with their particular condition.
Strength of construct validity varied among instruments. Less than half of measures empirically justified their proposed subscales. This is a critical omission, particularly when claiming that subscales are measuring discrete aspects of the overarching construct (eg, LPR). Such domains within LPR may at face value appear to be discrete, and many instruments instruct that subscales be scored separately. However, statistical justification is lacking to ensure their independence and that they are not measuring overlapping aspects of the construct.
While the ability to monitor change in LPR symptoms or quality of life is an attribute that most measures espouse, few instruments adequately demonstrated responsiveness to change. In this analysis, only 2 instruments met this criterion (RSI, LPR-HRQL). 21, 24 It is possible that others may demonstrate responsiveness to change in future studies. Nonetheless, based on their initial development, most PRO measures may not be appropriate for, and could give spurious results in, clinical trials and other comparative effectiveness studies.
A minority of measures provided information on how to interpret the score. 21, 23, 24 Interpreting the meaning of scores is a common problem faced by end users and hinders the clinical utility of these instruments. The RSI and PRSQ provided a cutoff for abnormal, thus allowing dichotomization but not gradation of scores for scaling. The clinically important change calculated for each domain within the LPR-HRQL is a valuable feature for end users, who otherwise would have to evaluate for statistical differences in scores that may lack clinical significance. 47 However, even this important change was based on physician perception of severity rather than what mattered to the patient. Several strategies to determine a clinically important change exist. 47 Omitting this feature of interpretability represents a weakness in most LPR-related PRO measures and limits their usefulness in clinical and research applications.
Incomplete questionnaires are also common occurrences in clinical practice and research applications. Implications of missing data can be significant, particularly if systematic, thus introducing bias. Many techniques for dealing with incomplete data exist, but only the PRSQ provided a framework. Additionally, no instrument described its literacy level. Respondents who do not understand the questions are less likely to complete them, which can result in bias based on patient educational level.
At present, a sensitive and specific criterion objective diagnostic test for LPR is lacking; therefore, PRO measures are often used in the diagnostic process for these patients. Available PRO measures have important developmental and psychometric limitations. Care should be exercised to understand the developmental characteristics of PRO measures before selecting and advocating their use in research or clinical applications. Measures vary in their developmental strengths, and some might be helpful adjuncts to diagnostic testing in outcome assessment. Importantly, of the 7 measures identified, only the RSI and the LPR-HRQL measured aspects of responsiveness to change and could therefore be appropriately used to track clinical outcomes over time.
There are limitations to this review process. Despite the careful design, the search may not have captured all available literature, as it is poorly indexed. Hand searches were used to mitigate this limitation. We also limited our search to English publications only. Applicable PRO measures may have been published in other languages that this review did not capture. There is also the risk of subjectivity in scoring PRO measure characteristics. Every effort was made to minimize this risk by using 3 independent reviewers for each instrument considered.
Conclusions
PRO measures are currently a principal method of diagnosing LPR and monitoring effectiveness of targeted therapies. Despite their prominence, available PRO measures were constructed with disparate developmental rigor. Important thematic deficiencies among instruments include a lack of patient involvement in the item development process, variable construct validity (eg, responsiveness), and poor interpretability and scaling properties. However, several had important strengths and could be considered adjunctive outcomes in the assessment of patients with symptoms attributed to, or who have been diagnosed with, LPR. Care must be taken to understand the developmental characteristics of PRO measures before selecting, advocating for, and using them in research and clinical applications.
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